Cynata Therapeutics Limited (CYYNF)
USD 0.3
(117.39%)
USD 0.3
(117.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 12.26 Million AUD | -24.58% |
| 2023 | 16.26 Million AUD | 17.52% |
| 2022 | 13.83 Million AUD | 52.39% |
| 2021 | 9.08 Million AUD | -13.62% |
| 2020 | 10.51 Million AUD | 4.49% |
| 2019 | 10.06 Million AUD | 64.1% |
| 2018 | 6.13 Million AUD | -3.18% |
| 2017 | 6.33 Million AUD | 2.44% |
| 2016 | 6.18 Million AUD | 45.07% |
| 2015 | 4.26 Million AUD | 35.38% |
| 2014 | 3.14 Million AUD | 260.35% |
| 2013 | 873.43 Thousand AUD | -36.85% |
| 2012 | 1.38 Million AUD | -45.29% |
| 2011 | 2.52 Million AUD | 32.64% |
| 2010 | 1.9 Million AUD | 34.26% |
| 2009 | 1.41 Million AUD | -11.67% |
| 2008 | 1.6 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 5.25 Million AUD | 0.0% |
| 2024 Q1 | 3.54 Million AUD | -61.36% |
| 2024 Q2 | 6.94 Million AUD | 96.04% |
| 2024 FY | 12.26 Million AUD | -24.58% |
| 2023 FY | 16.26 Million AUD | 17.52% |
| 2023 Q1 | 3.48 Million AUD | -30.79% |
| 2023 Q3 | 4.65 Million AUD | -31.88% |
| 2023 Q4 | 9.17 Million AUD | 96.99% |
| 2023 Q2 | 6.83 Million AUD | 95.99% |
| 2022 Q3 | 2.58 Million AUD | 152.76% |
| 2022 Q2 | 1.02 Million AUD | -74.71% |
| 2022 FY | 13.83 Million AUD | 52.39% |
| 2022 Q1 | 4.05 Million AUD | -5.36% |
| 2022 Q4 | 5.03 Million AUD | 94.59% |
| 2021 Q2 | 4.81 Million AUD | 96.33% |
| 2021 Q1 | 2.45 Million AUD | -31.42% |
| 2021 FY | 9.08 Million AUD | -13.62% |
| 2021 Q3 | 2.21 Million AUD | -54.12% |
| 2021 Q4 | 4.28 Million AUD | 93.67% |
| 2020 Q4 | 3.57 Million AUD | 92.45% |
| 2020 Q1 | 3.53 Million AUD | -35.48% |
| 2020 FY | 10.51 Million AUD | 4.49% |
| 2020 Q2 | 6.93 Million AUD | 96.03% |
| 2020 Q3 | 1.85 Million AUD | -73.18% |
| 2019 Q1 | 2.2 Million AUD | 56.9% |
| 2019 Q2 | 2.2 Million AUD | -0.0% |
| 2019 FY | 10.06 Million AUD | 64.1% |
| 2019 Q4 | 5.48 Million AUD | 95.02% |
| 2019 Q3 | 2.81 Million AUD | 27.25% |
| 2018 Q4 | 1.4 Million AUD | 0.0% |
| 2018 Q2 | 1.63 Million AUD | -0.0% |
| 2018 Q1 | 1.63 Million AUD | -9.25% |
| 2018 FY | 6.13 Million AUD | -3.18% |
| 2018 Q3 | 1.4 Million AUD | -13.82% |
| 2017 Q4 | 1.8 Million AUD | 0.0% |
| 2017 FY | 6.33 Million AUD | 2.44% |
| 2017 Q1 | 1.39 Million AUD | 3.3% |
| 2017 Q3 | 1.8 Million AUD | 28.81% |
| 2017 Q2 | 1.39 Million AUD | -0.0% |
| 2016 FY | 6.18 Million AUD | 45.07% |
| 2016 Q2 | 1.74 Million AUD | -0.0% |
| 2016 Q1 | 1.74 Million AUD | 32.6% |
| 2016 Q4 | 1.35 Million AUD | 0.0% |
| 2016 Q3 | 1.35 Million AUD | -22.25% |
| 2015 Q3 | 1.31 Million AUD | 79.53% |
| 2015 Q4 | 1.31 Million AUD | 0.0% |
| 2015 Q2 | 731.03 Thousand AUD | 0.0% |
| 2015 Q1 | 731.03 Thousand AUD | 6.71% |
| 2015 FY | 4.26 Million AUD | 35.38% |
| 2014 Q4 | 685.08 Thousand AUD | 0.0% |
| 2014 Q3 | 685.08 Thousand AUD | -22.9% |
| 2014 Q2 | 888.62 Thousand AUD | -0.0% |
| 2014 Q1 | 888.62 Thousand AUD | 222.07% |
| 2014 FY | 3.14 Million AUD | 260.35% |
| 2013 Q4 | 275.91 Thousand AUD | 0.0% |
| 2013 FY | 873.43 Thousand AUD | -36.85% |
| 2013 Q3 | 275.91 Thousand AUD | 0.0% |
| 2012 FY | 1.38 Million AUD | -45.29% |
| 2011 FY | 2.52 Million AUD | 32.64% |
| 2010 FY | 1.9 Million AUD | 34.26% |
| 2009 FY | 1.41 Million AUD | -11.67% |
| 2008 FY | 1.6 Million AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -221.063% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 85.867% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -4586.229% |
| SQZ Biotechnologies Company | 85.61 Million USD | 85.675% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -320.579% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 58.498% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 67.079% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -716.638% |
| Marizyme, Inc. | 19.23 Million USD | 36.252% |
| Genus plc | 147.7 Million USD | 91.696% |
| Pharming Group N.V. | 225.49 Million USD | 94.561% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -498.675% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -814.25% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -47.081% |
| ContraFect Corporation | 56.88 Million USD | 78.44% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -729.421% |
| IMV Inc. | 37.7 Million USD | 67.475% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -339.552% |
| ONE Bio Corp. | 6.44 Million USD | -90.337% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 85.729% |
| Mesoblast Limited | 5.9 Million USD | -107.812% |
| MultiCell Technologies, Inc. | 567.42 USD | -2161452.289% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 50.374% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.514% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3048.396% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -366.793% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -149.396% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1133.686% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -597.007% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -82.57% |
| Skye Bioscience, Inc. | 13.54 Million USD | 9.466% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -557.867% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -39.706% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 49160.32% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -178.204% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -143.256% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 23.392% |
| Accustem Sciences Inc. | 3.74 Million USD | -227.381% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2205.631% |
| Q BioMed Inc. | 3.43 Million USD | -256.893% |
| GB Sciences, Inc. | 1.42 Million USD | -763.429% |
| Alpha Cognition Inc. | 9.7 Million USD | -26.371% |
| CSL Limited | 3.44 Billion USD | 99.644% |
| Agentix Corp. | 1.37 Million USD | -794.115% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 87.652% |
| Enzolytics Inc. | 2.17 Million USD | -462.746% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | 3.516% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -235.965% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -568.362% |
| argenx SE | 1.53 Billion USD | 99.2% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 78.647% |
| HST Global, Inc. | 140.9 Thousand USD | -8604.379% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1074.816% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -990.317% |
| Halberd Corporation | 74.84 Thousand USD | -16287.964% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -409.997% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -260.21% |
| Zenith Capital Corp. | 8.94 Million USD | -37.147% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -676.588% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -399.531% |
| AVAX Technologies, Inc. | 7.31 Million USD | -67.779% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -7051.275% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -538.505% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -70303.995% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -397.214% |
| Helix BioMedix, Inc. | 1.97 Million USD | -521.951% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -12.865% |
| Kadimastem Ltd | 2.41 Million USD | -408.901% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 46.615% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -6658.178% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -818.436% |
| LadRx Corporation | 3.81 Million USD | -221.767% |
| Cell Source, Inc. | 4.32 Million USD | -183.563% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2852.034% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1228.094% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1228.094% |
| Affymax, Inc. | 39.38 Million USD | 68.859% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2111.734% |
| Itoco Inc. | 919.14 Thousand USD | -1234.404% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -189.379% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -996.075% |
| International Stem Cell Corporation | 5.27 Million USD | -132.69% |
| CytoDyn Inc. | 18.05 Million USD | 32.08% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -48630.899% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -5473.06% |
| Qrons Inc. | 643.67 Thousand USD | -1805.471% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -763.865% |
| SYBLEU INC | 160.87 Thousand USD | -7523.934% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -450.033% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1747.151% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -575.271% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -23199.039% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -60191.402% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 66.18% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -658.04% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1566.825% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -294.249% |
| Neutra Corp. | 243.82 Thousand USD | -4930.362% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 29.741% |
| PureTech Health plc | 144.59 Million USD | 91.518% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 40.141% |
| IXICO plc | 4.7 Million USD | -160.571% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -39.423% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 89.584% |
| CSL Limited | 3.89 Billion USD | 99.685% |
| Cellectis S.A. | 97.32 Million USD | 87.397% |